Family Oddball, and a New Class of Safe Oral Autoimmune & Inflammatory Disease Treatment with Blockbuster Potential
On day one of the JPM 2021 conference, CEO Giovanni Caforio of Bristol Myers Squibb – inheritor of Celgene’s former first presenting slot – took the virtual stage to highlight BMS’s biggest new products.
By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Just before I chaired a Board meeting last year, I spent a frustratingly painful hour going through many of the uncomfortable details of my divorce process and a set of emotional custody issues with my lawyers. Immediately after hanging up, with only minutes of transition, I put on my best poker face and dropped into the Board zoom with one of my portfolio companies. With a smile and some attempt at humor, I kicked off the meeting. I chaired it fine, I think, but throughout the meeting my head was rattling around with angst, disappointment, frustration, and all the other negative energy that many divorces are bathed in. I’m sure it affected my engagement in this instance, and in many others with similar dynamics for the past couple years. And my blogging has suffered. Life isn’t always easy, and divorces are emotional rollercoasters.
“You did nothing wrong,” said the Department of Public Health contact tracer who called my spouse late on January 2nd, “you wore a mask and followed all the safety guidelines. We may never know ultimately how you got it.” The sentiment brought no relief – our whole family, myself included, now have Covid.
By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. This blog is dedicated to the front-line healthcare workers, essential service workers, scientists, patients, and their families who confront COVID-19 every day, and in reverent remembrance of all of those who have lost their lives to this dread disease.
2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism.
A look back at 2020 and to the future at Atlas Venture.
View the newsletter.